A Phase 1 interventional study of MK-8527 in Hepatic Impairment and Healthy Participants, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to learn what happens to MK-8527 in a person's body over time (a pharmacokinetic [PK] study). Researchers will compare what happens to MK-8527 in the body when it is given to healthy participants and participants with mild and moderate hepatic (liver) impairment.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main inclusion criteria include but are not limited to the following:
All participants:
Participants with Mild HI (Group 1) and Moderate HI (Group 2):
Healthy Control Participants (Group 3):
- Healthy with no medical history, physical examination, clinical laboratory profiles, vital signs, and ECGs
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
All participants:
Participants with Mild HI (Group 1) and Moderate HI (Group 2):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will receive a single dose of MK-8527 on Day 1.
Drug: MK-8527
All participants will receive a single dose of MK-8527 on Day 1.
Drug: MK-8527
All participants will receive a single dose of MK-8527 on Day 1.
Drug: MK-8527
Oral administration
Area under the concentration versus time curve from 0 to the time of the last quantifiable sample (AUC0-last) of MK-8527
Plasma samples will be collected at pre-specified timepoints to determine the AUC0-last of MK-8527.
Time frame: Predose and at designated timepoints up to 168 hours post dose
Area under the concentration versus time curve from 0 to infinity (AUC0-inf) of MK-8527
Plasma samples will be collected at pre-specified timepoints to determine the AUC0-inf of MK-8527.
Time frame: Predose and at designated timepoints up to 168 hours post dose
Maximum Observed Concentration (Cmax) of MK-8527
Plasma samples will be collected at pre-specified timepoints to determine the Cmax of MK-8527.
Time frame: Predose and at designated timepoints up to 168 hours post dose
Time to Maximum Concentration (Tmax) of MK-8527
Plasma samples will be collected at pre-specified timepoints to determine the Tmax of MK-8527.
Time frame: Predose and at designated timepoints up to 168 hours post dose
Apparent Terminal Half-life (t1/2) of MK-8527
Plasma samples will be collected at pre-specified timepoints to determine the t1/2 of MK-8527.
Time frame: Predose and at designated timepoints up to 168 hours post dose
Apparent Clearance (CL/F) of MK-8527
Plasma samples will be collected at pre-specified timepoints to determine the CL/F of MK-8527.
Time frame: Predose and at designated timepoints up to 168 hours post dose
Apparent Volume of Distribution During Terminal Phase (Vz/F) of MK-8527
Plasma samples will be collected at pre-specified timepoints to determine the Vz/F of MK-8527.
Time frame: Predose and at designated timepoints up to 168 hours post dose
Number of Participants Who Experience One or More Adverse Events (AEs)
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
Time frame: Up to approximately 29 days
Number of Participants Who Discontinue Study Due to an AE
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
Time frame: Up to approximately 29 days
AUC0-inf of MK-8527-triphosphate (TP) in peripheral blood mononuclear cell (PBMCs)
Blood samples will be collected to determine the AUC0-inf of MK-8527-TP.
Time frame: Predose and at designated timepoints up to 672 hours post dose
Area under the concentration versus time curve from 0 to 672 hours after dosing (AUC0-672hrs) of MK-8527-TP in PBMCs
Blood samples will be collected to determine the AUC0-672 of MK-8527-TP.
Time frame: At designated timepoints pre dose and up to approximately 672 hours post dose
Cmax of MK-8527-TP in PBMCs
Blood samples will be collected to determine the Cmax of MK-8527-TP.
Time frame: Predose and at designated timepoints up to 672 hours post dose
Concentration at 672 Hours (C672) of MK-8527-TP in PBMCs
Blood samples will be collected to determine the C672 of MK-8527-TP.
Time frame: Predose and at designated timepoints up to 672 hours post dose
Tmax of MK-8527-TP in PBMCs
Blood samples will be collected to determine the Tmax of MK-8527-TP.
Time frame: Predose and at designated timepoints up to 672 hours post dose
T1/2 of MK-8527-TP in PBMCs
Blood samples will be collected to determine the Tmax of MK-8527-TP.
Time frame: Predose and at designated timepoints up to 672 hours post dose
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Sep 2025 to primary completion in Feb 2026, 4 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alimatravir